Scientists at the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust used a drug made from a genetically modified form of herpes simplex — the cold sore virus — to attack tumors in cancer patients' bodies, developing a cutting-edge form of cancer therapy in the process.

That patient, Krzysztof Wojkowski from West London, underwent the experimental therapy after he received a diagnosis of salivary gland cancer 2017.

All in all, of the 40 total patients participating in the trial, three out of nine that received only the RP2 injection had their tumors shrink, while seven out of 30 who received a combined treatment of RP2 of another cancer drug nivolamb also similarly benefitted.